Determining Patterns In Trial Experiences of Parkinson's Disease Patients

Parkinson Disease Clinical Trial

Official title:

An In Depth Study Examining Patterns in the Clinical Trial Experiences of Parkinson's Disease Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05685329
• Other study ID #: 87526739
• Status: Not yet recruiting
• Start date: February 2024
• Est. completion date: February 2026

Study information

• Verified date: June 2023
• Source: Power Life Sciences Inc.
• Contact: Michael B Gill
• Phone: (415) 900-4227
• Email: bask[@]withpower.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Historically, participation in clinical studies is highly skewed towards particular demographic groups of people.

This study will invite several participants to gather a wide range of information on clinical trial experiences for Parkinson's Disease patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of Parkinson's Disease.

The data collected from this study will help improve future outcomes for all Parkinson's Disease patients as well as those in under-represented demographic groups.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: February 2026
• Est. primary completion date: February 2025
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patient plans to participate in an interventional clinical trial for the condition of Parkinson's Disease

• Patient has been diagnosed with a type of Parkinson's Disease

• Patient is at least 50 to 80 years of age

• Patient has access to a home internet connection in order to provide regular updates through the course of the study

Exclusion Criteria:

• Patient has an ECOG score of 4 or higher

• Patient is not able to provide consistent digital updates as per study requirements

• Patient does not complete or agree to terms outlined in the Informed Consent Form

Related Conditions & MeSH terms

• Parkinson Disease

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Power Life Sciences Inc.

References & Publications (3)

Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. — View Citation

McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, Stott SRW. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update. J Parkinsons Dis. 2022;12(4):1073-1082. doi: 10.3233/JPD-229002. — View Citation

Reich SG, Savitt JM. Parkinson's Disease. Med Clin North Am. 2019 Mar;103(2):337-350. doi: 10.1016/j.mcna.2018.10.014. Epub 2018 Dec 3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients who decide to enroll in an Parkinson's Disease clinical trial		3 months
Primary	Rate of patients who remain in Parkinson's Disease clinical trial to trial completion		12 months